Gyre Therapeutics (NASDAQ:GYRE) Trading Up 7.9% – Should You Buy?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) was up 7.9% on Thursday . The company traded as high as $6.04 and last traded at $6.14. Approximately 24,311 shares traded hands during mid-day trading, a decline of 73% from the average daily volume of 90,412 shares. The stock had previously closed at $5.69.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on GYRE shares. Weiss Ratings downgraded shares of Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Wall Street Zen downgraded shares of Gyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Zacks Research downgraded shares of Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, March 16th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $17.00.

Gyre Therapeutics Stock Up 8.7%

The stock has a market capitalization of $600.13 million, a price-to-earnings ratio of -68.54 and a beta of 1.90. The company’s 50-day simple moving average is $7.01 and its 200 day simple moving average is $7.49.

Gyre Therapeutics (NASDAQ:GYRE) last posted its earnings results on Thursday, March 12th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04). The business had revenue of $37.20 million for the quarter, compared to analyst estimates of $36.30 million. Gyre Therapeutics had a positive return on equity of 3.13% and a negative net margin of 5.44%. On average, equities analysts expect that Gyre Therapeutics, Inc. will post -0.3 earnings per share for the current fiscal year.

Insider Transactions at Gyre Therapeutics

In other Gyre Therapeutics news, CEO Ying Luo sold 10,136 shares of the company’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $8.04, for a total transaction of $81,493.44. Following the completion of the sale, the chief executive officer directly owned 2,565,226 shares in the company, valued at $20,624,417.04. This represents a 0.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Weiguo Ye sold 12,820 shares of the company’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $6.15, for a total transaction of $78,843.00. Following the sale, the chief operating officer owned 700,000 shares of the company’s stock, valued at $4,305,000. This trade represents a 1.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 32,535 shares of company stock valued at $219,580 over the last 90 days. Corporate insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On Gyre Therapeutics

A number of hedge funds have recently bought and sold shares of GYRE. Bank of America Corp DE boosted its holdings in Gyre Therapeutics by 40.4% during the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock valued at $84,000 after acquiring an additional 1,996 shares during the period. Geode Capital Management LLC boosted its holdings in Gyre Therapeutics by 28.6% during the second quarter. Geode Capital Management LLC now owns 401,709 shares of the company’s stock valued at $2,953,000 after acquiring an additional 89,390 shares during the period. JPMorgan Chase & Co. boosted its holdings in Gyre Therapeutics by 84.6% during the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock valued at $47,000 after acquiring an additional 2,961 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Gyre Therapeutics by 77.8% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after acquiring an additional 3,244 shares during the period. Finally, Strs Ohio boosted its holdings in Gyre Therapeutics by 58.6% during the third quarter. Strs Ohio now owns 21,100 shares of the company’s stock valued at $157,000 after acquiring an additional 7,800 shares during the period. 23.99% of the stock is currently owned by institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.